glp 1 agonist in ckd The potential of GLP-1 receptor agonists type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice SGLT2 vs GLP-1 for CKD:

Abstract Chronic kidney disease (CKD) remains a major public health problem, with type 2 diabetes and obesity representing key risk factors worldwide

As with any dietary change, individuals with specific medical conditions or those on medication should discuss with their healthcare provider

Importantly, both groups improved their metabolic health, but the HT + GLP-1 group did better

Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits

Basith, S., Manavalan, B., Hwan Shin, T

GLP-1 receptor agonists lower HbA1c by 11.5% but this may be dependent of the type of GLP-1 receptor agonist prescribed, the dosage, baseline HbA1c levels and glucose-lowering co-medication [24]